Press releases

17 September, 2021

Abliva to participate in World Mitochondrial Disease Week 2021

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases, today announces that the compan ...

17 September, 2021

Abliva drug candidate NV354 to progress to clinical development following positive regulatory review

Abliva AB (Nasdaq Stockholm: ABLI), a clinical-stage biopharmaceutical company developing medicines for the treatment of rare and severe primary mitochondrial diseases (PMD), today announced that a se ...

16 September, 2021

Meet Abliva’s CEO live: Fireside Chat in Stockholm and Lund

20 May, 2021

Regulatory

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) today on May 20, 2021 held its Annual General Meeting (“AGM”). Due to the continued spread of the coronavirus and the authorities’ regula ...

19 May, 2021

Regulatory

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

29 April, 2021

Regulatory

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Abliva AB (Nasdaq Stockholm: ABLI) (”Abliva” or the ”Company”) has today held an Extraordinary General Meeting. Due to the continued spread of the coronavirus and the authorities’ regulations/advice o ...

19 April, 2021

Regulatory

Notice of Annual General Meeting of Abliva AB (publ)

The shareholders of Abliva AB (publ), corporate identity number 556595-6538, are hereby convened to the Annual General Meeting on Thursday 20 May 2021.

31 March, 2021

Regulatory

Abliva

Press releases

Abliva to participate in World Mitochondrial Disease Week 2021

Abliva drug candidate NV354 to progress to clinical development following positive regulatory review

Meet Abliva’s CEO live: Fireside Chat in Stockholm and Lund

Resolutions from Annual General Meeting in Abliva AB (publ)

Abliva reports positive clinical Phase 1a/b results for KL1333 including signs of efficacy in PMD patients

Resolutions at the Extraordinary General Meeting in Abliva AB (publ)

Notice of Annual General Meeting of Abliva AB (publ)

Notice of Extraordinary General Meeting of Abliva AB (publ)

Abliva reports completion of KL1333 Phase 1a/b study

Abliva appoints Ellen Donnelly as new CEO as it enters a new stage in its development

Abliva Announces Termination of License Agreement with Fortify Therapeutics

Abliva receives positive regulatory feedback from UK MHRA on KL1333 Phase II/III study plan